newsfilter
← Latest News
Business Wire·

NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy

-- First randomized controlled trial of neuromodulation in drug-resistant idiopathic generalized epilepsy (IGE) -- -- 18-month data show a 77% median reduction in generalized tonic-clonic (GTC) seizures, supporting